Correspondence 0001193125-24-179664 from Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc.
Date: July 16, 2024 · CIK: 0001817241 · Accession: 0001193125-24-179664
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280568
Letter
July 16, 2024
Jefferies LLC
520 Madison Avenue
New York, New York 10022
TD Securities (USA) LLC
1 Vanderbilt Avenue
New York, New York 10017
Cantor Fitzgerald & Co.
110 E. 59th St., 6th Floor
New York, New York 10020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Sasha Parikh
Lynn Dicker
Lauren Hamill
Jason Drory
Re: Artiva Biotherapeutics, Inc.
Registration Statement on Form S-1
(File No. 333-280568)
Acceleration Request
Requested Date: July 18, 2024
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), we, as representatives of the several underwriters (the “Representatives”), hereby join in the request of Artiva Biotherapeutics, Inc., a Delaware corporation (the “Registrant”), that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time on July 18, 2024, or as soon thereafter as practicable, or at such other time as the Registrant or its outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Securities Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We, the undersigned Representatives, have and will, and we have been informed by the participating underwriters that they have and will, comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, in connection with the proposed offering.
[Remainder of page intentionally left blank]
Very truly yours,
Acting severally on behalf of themselves and the several underwriters
Show Raw Text
CORRESP 1 filename1.htm CORRESP July 16, 2024 Jefferies LLC 520 Madison Avenue New York, New York 10022 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Cantor Fitzgerald & Co. 110 E. 59th St., 6th Floor New York, New York 10020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Sasha Parikh Lynn Dicker Lauren Hamill Jason Drory Re: Artiva Biotherapeutics, Inc. Registration Statement on Form S-1 (File No. 333-280568) Acceleration Request Requested Date: July 18, 2024 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), we, as representatives of the several underwriters (the “Representatives”), hereby join in the request of Artiva Biotherapeutics, Inc., a Delaware corporation (the “Registrant”), that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time on July 18, 2024, or as soon thereafter as practicable, or at such other time as the Registrant or its outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective. Pursuant to Rule 460 under the Securities Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement. We, the undersigned Representatives, have and will, and we have been informed by the participating underwriters that they have and will, comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, in connection with the proposed offering. [Remainder of page intentionally left blank] Very truly yours, Acting severally on behalf of themselves and the several underwriters JEFFERIES LLC TD SECURITIES (USA) LLC CANTOR FITZGERALD & CO. JEFFERIES LLC By: /s/ Matthew Kim Name: Matthew Kim Title: Managing Director, Joint Head of US Biotech TD SECURITIES (USA) LLC By: /s/ Tanya Joseph Name: Tanya Joseph Title: Managing Director CANTOR FITZGERALD & CO. By: /s/ Jason Fenton Name: Jason Fenton Title: Global Co-Head of ECM [Signature Page to Underwriters’ Acceleration Request Letter]